In vitro apoptosis induction ability of methanolic extract of *Paramignya trimera* root (Xao tam phan) in breast cancer stem cells

Sinh Truong Nguyen[1,2], Le Van Manh Hung[1], Nguyen Thi Thanh Mai[3], Nguyen Trung Nhan[3], Nguyen Xuan Hai[3], Ngoc Kim Phan[1], Kiet Truong Dinh[4], Phuc Van Pham[1,2,5,*]

[1]*Stem Cell Institute, VNUHCM University of Science, Ho Chi Minh City, Viet Nam*

[2]*Laboratory of Cancer Research, VNUHCM University of Science, Ho Chi Minh City, Viet Nam*

[3]*Faculty of Chemistry, VNUHCM University of Science, Ho Chi Minh City, Viet Nam*

[4]*Medical Genetic Institute, Ho Chi Minh City, Viet Nam*

[5]*Laboratory of Stem Cell Research and Application, VNUHCM University of Science, Ho Chi Minh City, Viet Nam*

Correspondence

Phuc Van Pham, Stem Cell Institute, VNUHCM University of Science, Ho Chi Minh City, Viet Nam

Laboratory of Cancer Research, VNUHCM University of Science, Ho Chi Minh City, Viet Nam

Laboratory of Stem Cell Research and Application, VNUHCM University of Science, Ho Chi Minh City, Viet Nam

Email: pvphuc@hcmuns.edu.vn

VNU-HCM Press

ABSTRACT

Objective: Cancer has been considered as one of the world's leading causes of death. Recently, the *Paramignya trimera* plant, locally called ``Xao Tam Phan'', has become a popular Vietnamese medicinal herb that is used as alternative medicine for cancer treatment support with minimal side effects. In this study, we aimed to demonstrate the cytotoxicity of methanolic extract of *Paramignya trimera* on a Vietnamese breast cancer stem cell line (VNBRCA1) *in vitro*. **Methods**: We used the MTT assay to determine the cytotoxicity of the extract on VNBRCA1 cells and human fibroblast (HF) cell line was used as a control for the plant extract treatment. Clinically used anticancer drug, doxorubicin, was used as a control drug (for relative comparison to the plant extract) to evaluate the selective cytotoxicity of the plant extract on VNBRCA1 and HF cells. We examined the apoptosis induction by the plant extract on VNBRCA1by Annexin V/7AAD staining and flow cytometry analysis. In addition, the morphology of apoptotic nuclei of treated cells was observed by fluorescent microscopy using double fluorescent staining: Hoechst 33342 and propidium iodide (PI). **Results**: In comparison between the cytotoxicity of the plant extract and Doxorubicin on both cell lines (VBRCA1 and HF), we observed that plant extract was selectively cytotoxic against VNBRCA1 with an IC50 value of 106±10 μg/mL, while Doxorubicin was discriminatorily cytotoxic against HF with an IC50 value of 0.135±0.09 μg/mL. We also found that the plant extract induced apoptosis VNBRCA1 in a dose-dependent manner. In addition, fluorescent microscopy revealed disintegrated nuclei of plant extract-treated cells, representing a hallmark of apoptosis. **Conclusions**: These results showed that *Paramignya trimera* methanolic extract selectively killed VNBRCA1 cell lines, indicating that *Paramignya trimera* methanolic extract may represent a potential agent for cancer treatment.

Key words: Selective, anticancer, Paramignya trimera, Vietnamese breast cancer cell (VNBRCA1), apoptosis

INTRODUCTION

The treatment of cancer has many challenges due to factors such as the effectiveness of therapies, tumor recurrence, and side effects of current therapies (including surgery, radiotherapy, and chemotherapy). Among the cancer types, breast cancer is the one of the leading causes of death worldwide. In 2012, there were nearly 1.7 million cases diagnosed and 522,000 deaths worldwide[1]. In Vietnam, in 2008, breast cancer occupied the highest proportion of all types of cancer: 29.7% in Hanoi and 19.4% in Ho Chi Minh City[2]. In 2003, Al-hajj and his team discovered that breast cancer stem cells with $CD44^{+}CD24^{-/low}$ expression could initiate tumor formation and play an important role in metastasis as well as tumor recurrence[3]. Thus, it would be potentially beneficial to alternatively or additionally treat cancer by attacking the cancer stem cells.

For a long period of time in human history, natural plants have been used as useful remedies in a variety of aspects, such as for antimicrobial, anti-inflammatory, and anti-carcinogenic applications. To solve the health problems caused by cancer diseases nowadays, it is necessary for scientists to search for potential anticancer compounds from natural resources. The strategy for this drug development starts with the investigation of the effects of plant extracts on different cancer cell lines to identify the potential targets. This approach has been used to identify many clinically used anticancer agents in the past. Indeed, more than 60% of currently available drugs are natural compounds or structually related to them[4]. For instance, Podophyllotoxin is the most abundant lignan of Podophyllin isolated from species of genera *Podophyllum*, Camptothecin is a quinolone alkaloid with antitumor property derived from *Camptoteca acuminata*[5,6], and Paclitaxel (Taxol®) is a diteprene

with a taxane nucleus extracted from Taxus brevifolia[7,8].

Paramignya trimera (*P. trimera*) plant, called "Xao tam phan" in Vietnamese, has been used as medicinal plant for supporting cancer treatment in patients. *Paramignya trimera*, which belongs to *Paramignya* genus and Rutaceae family, is an endemic plant of Vietnam and Thailand. In Vietnam, *P. trimera* is mostly distributed in the southern part of the country. Several diseases have been reported to benefit from *P. trimera* plant extract. A recent study demonstrated that the crude methanolic extract of *P. trimera* has hepatoprotective and anticancer activity. Ostruthin was discovered to be a major compound in *P. trimera* roots and stems[9], and it was also demonstrated to be cytotoxic against pancreatic cancer cells[10]. In addition to ostruthin, several studies have identified some new coumarins which were shown to be promising and to have novel bioactivity[11]. For these reasons, we hypothesize that *P. trimera* might have cytotoxicity against breast cancer stem cells.

In this study, we investigated the effect of *P. trimera* plant on breast cancer stem cells (VNBRCA1) *in vitro*. VNBRCA1 was isolated from the breast tumor of a Vietnamese patient by the Stem Cell Research and Application Laboratory in a previous study, and has stem cell-like properties[12]. We sought to investigate the selective killing ability and the mode of cell death caused by *P. trimera* on VNBRCA1.

METHODS

Cell lines

VNBRCA1 cell line was isolated from a Vietnamese patient in 2012 by the Laboratory of Stem Cell Research and Application, University of Sciences, Ho Chi Minh City. VNBRCA1 was characterized by $CD44^+CD24^{-/low}$ phenotype and had the ability to initiate tumorigenesis *in vivo*[13]. Human fibroblasts (HF) were isolated from human skin collected from patients at Gia Dinh Hospital with signed consent. The use of skin sample were approved by the Institutional Ethical Committee (Stem Cell Institute, VNU-HCM University of Sciences). The VNBRCA1 and HF cells were cultured in 25 cm^2 flasks with DMEM/F12 (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich) and 1% penicillin/streptomycin antibiotic (ThermoFisher Scientific, Waltham, MA, USA) in a CO_2 incubator (Binder, Germany) with an atmosphere of 95% air, 5% CO_2 at 37°C.

Collection of plant material

The plant was collected at Ma Da forest in Dong Nai Culture and Nature Reserve of Dong Nai Province, Vietnam in April 2014. The plant was identified by Assoc. Ph.D. Hop Tran, Institute of Tropical Biology, Ho Chi Minh City, Vietnam. The voucher sample (MCE018) was preserved in the Division of Medicinal Chemistry, Faculty of Chemistry, University of Science, Viet Nam National University- Ho Chi Minh City, Viet Nam.

Extraction of plant material

The dried root of *P. trimera* plant (200 g) was cut into small pieces and extracted with MeOH (300 mL, reflux, 3h × 3). The MeOH solution was evaporated under reduced pressure to yield the MeOH extract (15 g).

Treatment of Doxorubicin and *Paramignya trimera* methanolic extract

Cells were cultured in medium with different concentrations of Doxorubicin (Sigma-Aldrich) and *P. trimera* extract for 48 h and 72 h, respectively. Briefly, after one day of pre-incubation for the attachment of VNBRCA1 cells to the culture surface, cells were treated with Doxorubicin at the concentration of 1000, 500, 250, 125, 75, 32.5, 16, 8, or 0 (μg/mL). At the same time, cells were also treated with *P. trimera* extract at 200, 100, 50, 25, 12.5, 6, 3, 1.5, or 0 (mg/mL). Each concentration was tested in triplicate. Cell viability was measured by MTT assay. Each experiment was repeated three times. The data were analyzed by GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA).

Determination of IC$_{50}$ value by MTT assay

After cells were treated with chemotherapeutic agents, MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) assay was performed to determine the IC$_{50}$ value of Doxorubicin and *P. trimera* extract. Briefly, MTT agent was added into each well on the second day of Doxorubicin treatment and on the third day of plant extract treatment. Then, the plates were incubated at 37°C for 4 h. After that, MTT agent was removed from those wells. During the next step, dimethyl sulfoxide (DMSO) was added to wells and incubated for 15 min at 37°C. The OD value at 595 nm wavelength was measured by DTX880 machine (Beckman Coulter, USA). The IC$_{50}$ was determined based on the dose-response curve. The X-axis of the dose-response curve was the

logarithm of the different concentrations of the agent, and the Y-axis is the inhibition percentage calculated from the OD value. From this sigmoidal curve, IC_{50} (X value) was calculated by setting Y value as 50%.

Viability staining assay

Cell viability of VNBRCA1 at 250 μg/mL concentration was evaluated by Hoechst 33342/ PI staining. Skin human fibroblast (HF) cells were used as a control cell line. Briefly, VNBRCA1 and HF cells were treated with *P. trimera* extract at a concentration of 250 μg/mL; untreated cells were cultured in normal media complemented with solvent. At day 3 of treatment, cells were stained with Hoechst 33342/ PI. The final concentration of Hoechst 33342, as well as PI, was 1 μg/mL in culture media. Next, cells were incubated in an incubator with the condition of 37°C, 5% CO_2 for 5 minutes. Stained cells were observed under a fluorescent microscope.

Annexin V/ 7-AAD staining analysis by flow cytometry

The culture flask of VNBRCA1 was treated with *P. trimera* extract at 3 concentrations of 30, 60 and 125 μg/mL, for 3 days. After that, annexin V/7-AAD staining and flow cytometry techniques were performed to determine the mode of cell death. Briefly, all cells were detached from the flask surface by trypsin and centrifuged at 300 g to collect the pellet. After that, cells were stained with annexin-V-FITC and 7-AAD. Stained cells were analyzed by a BD FAC-SCalibur (BD Biosciences, San Jose, CA, USA) flow cytometer. Data was analyzed by CellQuest Pro software.

Statistical analysis

Data was analyzed by Graphpad Prism software (Graphpad Software Inc.) for the determination of IC50 value. All data were presented as the mean of triplicate experiments. Statistically significant difference was set as p<0.05.

RESULTS

Selective cytotoxic effect of *P. trimera* against VNBRCA1

After 3 days of treatment with 10 different concentrations of *P. trimera* extract (2000, 1000, 500, 250, 125, 62.5, 31.25, 15.63, 7.81, or 3.91 μg/mL; control), proliferation of *P. trimera* extract-treated cells was measured by MTT assay. The IC_{50} value of *P. trimera* extract on VNBRCA1 after 72 h was 106±10 μg/mL,

while IC_{50} of *P. trimera* extract on HF after 72 h was 310±8 μg/mL (**Figure 1**).

Similar to the method for calculating the IC_{50} of *P. trimera* extract, the OD value was measured to evaluate the dose-response inhibition of Doxorubicin (1, 0.5, 0.25, 0.125, 0.0625, 0.031, 0.016, or 0 (μg/mL) on VNBRCA1 and on HF cells. The IC_{50} value of Doxorubicin on VNBRCA1 after 48 h is 0.63±0.12 μg/mL while IC_{50} value of Doxorubicin on HF after 48 h was 0.135±0.09 μg/mL.

Based on the IC50 value of each agent on both VN-BRCA1 and HF, we determined the selectivity index (SI). This parameter reflects the selective toxicity of the agent against cancer cell but not normal cells. In this study, we calculated SI of the agent by the ratio of the IC_{50} *of the agent on HF* to the IC_{50} *of the agent on VNBRCA1* (**Table 1**):

$$SI = \frac{IC50 \text{ of agent on HF}}{IC50 \text{ of agent on VNBRCA1}}$$

The higher the SI, the more selective the toxicity of the agent against breast cancer cells (but not HF cells). Calculations of $SI_{extract}$ and $SI_{Doxorubicin}$ were performed to determine the selective cytotoxicity of both the plant extract and Doxorubicin against VNBRCA1.

SI of *P. trimera* extract on HF/VNBRCA1:

$$SI_{\textit{P.trimera extract}} = \frac{IC50 \text{ of extract on HF}}{IC50 \text{ of extract on VNBRCA1}} = \frac{310}{106} = 2.92$$

SI of Doxorubicin on HF/VNBRCA1:

$$SI_{Doxorubicin} = \frac{IC50 \text{ of Doxorubicin on HF}}{IC50 \text{ of Doxorubicin on VNBRCA1}} = \frac{0.135}{0.63} = 0.21$$

Difference between $SI_{\textit{P.trimera extract}}$ and $SI_{Doxorubicin}$

$$\frac{SI \text{ of extract}}{SI \text{ of Doxorubicin}} = \frac{2.9292}{0.2121} = 13.92$$

$SI_{\textit{P. trimera extract}}$ was nearly 14-fold higher than $SI_{Doxorubicin}$.

Hoechst 33342 is a blue-fluorescence dye and PI is a red-fluorescence dye; each has different excitation/emission wavelengths (350/461 nm and 536/617 nm, respectively). Hoechst 33342 can stain the DNA of both dead and living cells while PI is only permeable to dead cells. At a concentration of 250 μg/mL, *P. trimera* plant extract caused severe cell death to VNBRCA1 (red spots in **Figure 2**C), while *P. trimera* extract did not show toxicity in HF cells (**Figure 2 A**). This indicated the selective cytotoxic ability of *P. trimera* extract on VNBRCA1 cells.

Paramignya trimera extract induced apoptosis in VNBRCA1

The total apoptotic populations (late apoptosis in upper right quadrant and early apoptosis in lower right

Figure 1: **Inhibition curve of *P. trimera* extract and Doxorubicin on both VNBRCA1 and HF cell line. A**. The dose-response inhibition curve of HF and VNBRCA1 by *P. trimera* extract with the concentration 2000, 1000, 500, 250, 125, 62.5, 30, 15, 0 (ug/mL). **B**. The dose-response inhibition curve of Doxorubicin on VNBRCA1 and HF at the concentrations of 1, 0.5, 0.25, 0.125, 0.0625, 0.031, 0.016, or 0 µg/mL. The viable cells were evaluated by MTT assay after 3 days of treatment. The experiment was repeated three times. The curves represented 3 replications. The data was presented by mean±SD.

Table 1: **Summary of the IC$_{50}$ value and the selectivity index (SI)**

	IC50 on VNBRCA1	IC50 on HF	SI of VNBRCA1/HF
P. trimera extract	106±10 µg/ml	310±8 µg/ml	2.92
Doxorubicin	0.63±0.12 µg/ml	0.135±0.09 µg/ml	0.214

SI: selectivity index

quadrant) are shown in **Figure 3**; the % of apoptosis was 2.98% (for untreated cells), 4.37% (for the 30 µg/mL *P. trimera* extract sample), 6.99% (for the 62.5 µg/mL sample), and 20.97% (for the 125 µg/mL sample). The results also showed that the apoptosis percentage clearly increased when the concentration of *P. trimera* extract doubled, while the necrotic cell population was tightly augmented from 0.29% (in control sample) to 10% (in the 125 µg/mL sample). Viable cells were significantly reduced from 96% to 78%, in the 125 µg/mL *P. trimera* extract sample.

We used the plant extract at a concentration of 200 µg/mL, which is nearly double of the IC50 value of the *P. trimera* extract on VNBRCA1 to test effects of the extract on DNA damage. The results showed that the extract caused disintegrated nuclei in VNBRCA1 after 24 h of treatment, as compared to human fibroblast cells (where the extract did not induce much DNA disintegration) (**Figure 4**). This confirmed that the *P. trimera* extract can induce apoptosis in VNBRCA1 cells.

DISCUSSION

P.trimera has been traditionally used for a long time as a medicinal plant. The cytotoxic effects of *P. trimera*

extract on certain cell types (such as Hela and HepG2, but not for VNBRCA1) have been reported in several studies. In this paper, we demonstrated the evidence of selective cytotoxicity of the plant extract against VNBRCA1 cells compared to normal human fibroblast. Furthermore, we provided evidence of the apoptosis-inducing effect of *P. trimera* extract on VNBRCA1 *in vitro*.

The results from the MTT assay showed that the IC$_{50}$ of the *P. trimera* plant extract on VNBRCA1 was 106 µg/mL, which is about 3-fold lower than the IC50 value of the *P. trimera* extract on human skin fibroblasts (HF; a non-cancerous cell line), which was 310 µg/mL. This means that the *P. trimera* extract has a 3-fold stronger killing effect on VNBRCA1 cells than on HF cells. Thus, the *P. trimera* extract killed breast cancer stem cells (VNBRCA1), but had negligible side effects on normal human skin cells. A previous study showed that the methanolic extract of *P. trimera* was active against HepG2 and Hela cell lines with IC50 values of 39.61 and 5.36 µg/mL, respectively. The previously reported IC50 values of *P. trimera* on HepG2 and Hela also showed the selective toxicity of the plant extract in comparison to its IC50 value on HF in this study (**Figure 1**).

Meanwhile, we also investigated the cytotoxicity of Doxorubicin on VNBRCA1 and HF. Interestingly, the

Figure 2: **Hoechst 33342/PI- stained viable cells**. VNBRCA1 and HF cells were treated with plant extract *P. trimera* at a concentration 250 μg/mL. Untreated cells were cultured in normal media. After 3 days, cells were stained with Hoechst 33342/PI at a final concentration of 1 μg/mL for both dyes. The samples were observed under fluorescent microscopy after 10 min of incubation.


Figure 3: **Flow cytometry analysis of *P. trimera* extract-treated VNBRCA1 cells**. Breast cancer stem cells (VN-BRCA1) were treated with *P. trimera* extract at a concentration of 30, 62.5, or 125 μg/mL. The control sample was cultured in normal media supplemented with methanol solvent. After 24 hours of treatment, cells were analyzed by flow cytometry.

Figure 4: **Fluorescent images of disintegrated nuclei of *Paramignya trimera* extract-treated VNBRCA1 cells.** VNBRCA1 cells were treated with plant extract (200 μg/mL). Control cells is VNBRCA1 cells untreated with plant extract, these cells are cultured in normal condition. After 24 hours, cells were detached and co-stained with Hoechst 33342 and PI. Cells were then observed under fluorescent microscopy at 100X magnification. The white arrows indicate disintegrated nuclei.

IC_{50} of Doxorubicin on HF was 0.135 μg/ml, which was almost 4.5-fold lower than the IC_{50} of Doxorubicin on VNBRCA1 (0.63 μg/mL). Thus, Doxorubicin kills more normal cells (HF) than cancer cells (VNBRCA1) (**Figure 1**).

From the IC_{50} data from **Table 1**, we bring up the equation called selectivity index (SI), which is the ratio of (IC50 of the agent on HF)/(IC50 of the agent on VNBRCA1). The selectivity index was previously used to figure out the selective cytotoxic activity of synthesis drugs on human breast carcinoma MCF-7

compared to normal cell line[14]. In this study, the agent could be either *P. trimera* extract or Doxorubicin. The greater the SI value is, the more toxic the agent is against VNBRCA1 (but safer against HF). Therefore, calculations of $SI_{extract}$ and $SI_{Doxorubicin}$ were performed to compare the selective cytotoxicity of both *P. trimera* extract and Doxorubicin, on cancer cells (VNBRCA1) and normal cells (HF). The SI of the *P.trimera* extract was nearly 14-fold higher than that for Doxorubicin (2.92>0.214). From the above results, it can be concluded that the *P.trimera* extract not

only showed less toxicity on HF than on VNBRCA1, but also showed more selective toxicity than Doxorubicin. Because of its considerably high selective cytotoxicity, *P.trimera* extract could become a potential candidate as an anticancer agent.

Hoechst 33342/ PI staining results indicated that *P. trimera* extract showed cytotoxicity against VN-BRCA1 but not HF, at the concentration of 250 μg/mL (**Figure 2**). In other words, at this concentration, the extract was safe on HF, while a large population of VNBRCA1 underwent cell death. Taken together, the data show that *P. trimera* extract primarily displays a highly selective toxicity in cancer cells. However, in order to further examine the side effect index of the *P. trimera* extract, it was necessary to perform the cytotoxicity assay on other normal cell lines, such as non-cancerous breast cell line or normal liver cell line. In recent studies, the side effect index was similarly performed to compare the IC_{50} value of the agent on non-cancerous breast cell line and cancerous breast cell line [15], or to determine the IC_{50} value of the agent on Hep-G2 cell line versus normal liver cell line [16]. PI staining assay further showed the selective cytotoxicity of the *P. trimera* extract on the 2 cell lines, HepG2 and HF, but the result did not indicate whether the *P. trimera* extract induced apoptosis on HepG2 or not. The reason for this is that PI stained both necrotic cells and late apoptotic cells, thus PI staining only could not discriminate the two types of cell death [17–19].

Apoptosis induction of medicinal plant extract is an important characteristic required in cancer drug screening [20]. It is a more favorable mode of cell death than necrosis since cell death via necrosis can cause inflammation during treatment [21]. Apoptosis is characterized by chromatin condensation, cell membrane shrinkage, and DNA fragmentation. In this study, the apoptotic cell population from *P. trimera* extract-treated cells was firstly analyzed by flow cytometry. VNBRCA1 cells were cultured in medium complemented with *P. trimera* extract, with various concentrations (30, 60, or 125 μg/mL) of *P. trimera* for 24 hours, and then the apoptotic population was identified by Annexin V staining. Meanwhile, the necrotic population was identified by 7-AAD staining. The results showed that percentage of apoptotic population increased as concentrations of *P. trimera* extract were increased. The early and late apoptotic population was 2.98% (for untreated sample), 4.37% (for 30 μg/mL extract sample), 6.99% (for 60 μg/mL extract sample), and 20.97% (for 125 μg/mL extract sample) (**Figure 3**). Thus, the apoptosis induced by *P. trimera* extract appears to be dose-dependent.

However, the percentage of necrotic population was not significantly increased. Even at the highest concentration of *P. trimera* extract (125 μg/mL), the necrotic population was only 1%, which was not considerably different from the portion of apoptotic population (0.29 %) in the control sample. Recently, another study reported the dose-dependent apoptosis of MCF-7 breast cancer cell line treated with *Lepidium sativum* seed extract [22]. However, the authors reported that extracts of *Lepidium sativum* seeds also caused apoptosis in human skin fibroblasts at the same level as that of MCF-7 breast cancer cells. In general, the *Lepidium sativum* extract did not selectively kill cancer cells in comparison with the *P. trimera* extract. However, in our study, the *P. trimera* extract was tested only on VNBRCA1 cells and HF cells, so it is necessary to examine the cytotoxicity of this plant extract on other breast cancer cell lines. Based on those results, we can conclusively compare the *P. trimera* extract with other extracts evaluated in other studies.

Nuclei observation was performed in order to confirm the findings from the flow cytometry results which indicated that the extract had the ability to induce apoptosis. Disintegrated nuclei appeared in the fluorescent images when cells were treated *with P. trimera* extract, demonstrating that the treated cells underwent apoptosis. On the other hand, only a few dead cells were observed in the control sample and those cells did not show abnormal nuclei. These observations are in agreement with the flow cytometry results which indicating that the extract can induce apoptosis on VN-BRCA1 after a short period of incubation.

CONCLUSIONS

Overall, the results from this study suggest that *P. trimera* methanolic extract could be a potential anticancer agent. MTT assay results and microscopic images indicated that the cytotoxicity of the extract was dose-dependent. The *P. trimera* extract selectively killed the VNBRCA1 breast cancer cell line but not normal human fibroblast HF. In addition, *P. trimera* extract was shown to induce apoptosis in VNBRCA1 after a short term of incubation (24 hours). Further studies are warranted to investigate the antitumor properties of *P. trimera* extract *in vivo*. Identification of bioactivity compounds in *P. trimera* extract is also necessary. In conclusion, *P. trimera* could be a promising anti-proliferative agent against Vietnamese breast cancer cells.

ABBREVIATIONS

HF: human fibroblast
P. Trimera: Paramignya trimera
PI: propidium iodide
SI: selectivity index
VNBRCA1: Vietnamese breast cancer stem cell line

COMPETING INTERESTS

Authors declare no conflict of interest.

AUTHORS' CONTRIBUTIONS

Sinh and Hung carried out the IC50 study. Sinh helped to perform FCM assay and fluorescent of dis-intergrated nuclei experiment. Mai, Hai, Nhan participated in performing the extract from ***Paramignya trimera*** root. Ngoc and Kiet and Phuc helped to draft the manuscript.

ACKNOWLEDGMENTS

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):359–86. PMID: 25220842. Available from: 10.1002/ijc.29210.
2. Trieu PD, Mello-Thoms C, Brennan PC. Female breast cancer in Vietnam: a comparison across Asian specific regions. Cancer Biol Med. 2015;12(3):238–45. PMID: 26487968.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(7):3983–8. PMID: 12629218. Available from: 10.1073/pnas.0530291100.
4. Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol. 2007;9(12):767–76. PMID: 18158980. Available from: 10.1007/s12094-007-0138-9.
5. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2. J Am Chem Soc. 1966;88(16):3888–90. Available from: 10.1021/ja00968a057.
6. Chavan S, Pathak AB, Kalkote UR. Total synthesis of (+)-camptothecin via an intramolecular palladium-catalyzed cyclization strategy. Synlett. 2007;2007(17):3. Available from: 10.1055/s-2007-991054.
7. Kingston DG, Newman DJ. Taxoids: cancer-fighting compounds from nature. Curr Opin Drug Discov Devel. 2007;10(2):130–44. PMID: 17436548.
8. Camidge R. The Story of Taxol: Nature and Politics in the Pursuit of an Anti-Cancer Drug. BMJ. 2001;323(7304):115–115. Available from: 10.1136/bmj.323.7304.115/a.
9. Pham HB. N.M.K., Nguyen T.B.T, Isolation and quantitative analysis of ostruthin in the medicinal plant Paramignya trimera collected in Vietnam. Medicine Master. 2013;18(3):173–9.
10. Li F, Okamura Y, Dibwe DF, Awale S, Kadota S, Tezuka Y. Anti-austerity agents from Rhizoma et Radix Notopterygii (Qianghuo). Planta Med. 2012;78(8):796–9. PMID: 22516931. Available from: 10.1055/s-0031-1298463.
11. Cuong NM, Huong TT, Khanh PN, Tai NV, Ha VT, Son NT, et al. Paratrimerins A and B, Two New Dimeric Monoterpene-Linked Coumarin Glycosides from the Roots and Stems of Paramignya trimera. Chem Pharm Bull (Tokyo). 2015;63(11):945–9. PMID: 26521859. Available from: 10.1248/cpb.c15-00336.
12. Pham PV, Phan NL, Nguyen NT, Truong NH, Duong TT, Le DV, et al. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med. 2011;9(1):209. PMID: 22152097. Available from: 10.1186/1479-5876-9-209.
13. Pham PV, Vu BT, Nhan PLC, Thuy DT, et al. Isolation of Breast Cancer Stem Cells by Single-Cell Sorting. In: Ceccherini-Nelli, Matteoli B, editors. Biomedical tissue culture. Intech Open; 2012. p. 59–72. Available from: 10.5772/51506.
14. Badisa RB, Darling-Reed SF, Joseph P, Cooperwood JS, Latinwo LM, Goodman CB. Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells. Anticancer Res. 2009;29(8):2993–6. PMID: 19661306.
15. Abu N, Akhtar MN, Ho WY, Yeap SK, Alitheen NB. 3-Bromo-1-hydroxy-9,10-anthraquinone (BHAQ) inhibits growth and migration of the human breast cancer cell lines MCF-7 and MDA-MB231. Molecules. 2013;18(9):10367–77. PMID: 23985955. Available from: 10.3390/molecules180910367.
16. Al-Qubaisi M, Rozita R, Yeap SK, Omar AR, Ali AM, Alitheen NB. Selective cytotoxicity of goniothalamin against hepatoblastoma HepG2 cells. Molecules. 2011;16(4):2944–59. PMID: 21471934. Available from: 10.3390/molecules16042944.
17. Brauchle E, Thude S, Brucker SY, Schenke-Layland K. Cell death stages in single apoptotic and necrotic cells monitored by Raman microspectroscopy. Sci Rep. 2014;4(1):4698. PMID: 24732136. Available from: 10.1038/srep04698.
18. Denecker G, Vercammen D, Declercq W, Vandenabeele P. Apoptotic and necrotic cell death induced by death domain receptors. Cell Mol Life Sci. 2001;58(3):356–70. PMID: 11315185. Available from: 10.1007/PL00000863.
19. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol. 1998;60(1):619–42. PMID: 9558479. Available from: 10.1146/annurev.physiol.60.1.619.
20. Dixon SC, Soriano BJ, Lush RM, Borner MM, Figg WD. Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target. Ann Pharmacother. 1997;31(1):76–82. PMID: 8997471. Available from: 10.1177/106002809703100113.
21. Kiaris H, Schally AV. Apoptosis versus necrosis: which should be the aim of cancer therapy? Proc Soc Exp Biol Med. 1999;221(2):87–8. PMID: 10352117. Available from: 10.3181/00379727-221-44388.
22. Mahassni SH, Al-Reemi RM. Apoptosis and necrosis of human breast cancer cells by an aqueous extract of garden cress (Lepidium sativum) seeds. Saudi J Biol Sci. 2013;20(2):131–9. PMID: 23961228. Available from: 10.1016/j.sjbs.2012.12.002.

SCAN ME